Published online Nov 16, 2018. doi: 10.4253/wjge.v10.i11.348
Peer-review started: May 12, 2018
First decision: July 9, 2018
Revised: August 8, 2018
Accepted: October 8, 2018
Article in press: October 10, 2018
Published online: November 16, 2018
Processing time: 188 Days and 16.1 Hours
To prospectively evaluate the efficacy of submucosal injection of platelet-rich plasma (PRP) on endoscopic resection of large sessile lesions.
Eleven patients were submitted to endoscopic mucosal resection (EMR) with prior injection of PRP, obtained at the time of endoscopy. Patients were followed during 1 mo. The incidence of adverse events (delayed bleeding or perforation) and the percentage of mucosal healing (MHR) after 4 wk were registered.
EMR was performed in 11 lesions (46.4 mm ± 4 mm, range 40-70 mm). Delayed bleeding or perforation was not observed in any patient. Mean ulcerated area at baseline was 22.7 cm2 ± 11.7 cm2 whereas at week 4 were 2.9 cm2 ± 1.5 cm2. Patients treated with PRP showed a very high MHR after 4 wk (87.5%).
PRP is an easy-to-obtain solution with proven and favourable biological activities that could be used in advanced endoscopic resection.
Core tip: This was a prospective single-center study to evaluate the efficacy of submucosal injection of platelet-rich plasma (PRP) on 11 patients submitted to endoscopic resection of large lesions. PRP as lifting solution proved absence of delayed bleeding or perforation and strong healing activity.